UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.

BusinesswireApr 17 12:02 ET

UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment

UroGen Pharma (URGN) said Monday that the US Food and Drug Administration has accepted its Investigational New Drug application for UGN-103, a potential treatment for low-grade intermediate-risk non-m

MT NewswiresApr 15 08:49 ET

UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the man

BenzingaApr 15 08:11 ET

UroGen Pharma Ltd.'s (NASDAQ:URGN) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 11% Over Last Week

Yahoo FinanceApr 14 10:26 ET

UroGen Pharma Ltd.'s (NASDAQ:URGN) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 11% Over the Past Week

Key Insights Given the large stake in the stock by institutions, UroGen Pharma's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 9 shareholders I

Simply Wall StApr 13 08:42 ET

Two Buys; Two Holds, by Oppenheimer

Seeking AlphaApr 9 09:35 ET